Streetbeat News

Products Services

PHIO

Phio Pharmaceuticals Corp. (NASDAQ: PHIO) reported its Q3 2024 financial results and provided a business update. The company is advancing its lead product candidate, PH-762, in a Phase 1b clinical trial following a positive safety recommendation.

Portfolio Pulse from

November 14, 2024 | 11:00 pm

DIS

The Walt Disney Company is experiencing strong growth in its direct-to-consumer segment and margin expansion, leading to a 'Strong Buy' rating with a fair value of $130 per share. The company reported a 21.3% growth in adjusted operating profits for FY24, driven by Disney+ subscriber growth and improved cash flow margins. Disney expects double-digit EPS growth for FY26 and FY27, supported by investments in parks and cruise lines.

Portfolio Pulse from

November 14, 2024 | 11:00 pm

GFR

Greenfire Resources Ltd. (NYSE: GFR) reported its Q3 2024 financial and operational results, highlighting its focus on thermal energy production in Alberta, Canada.

Portfolio Pulse from

November 14, 2024 | 10:45 pm

NGVC

Natural Grocers is promoting its Thanksgiving offerings, including turkey reservations, festive recipes, and special deals from November 23-26, 2024. The company aims to attract customers with savings and ease the holiday shopping experience.

Portfolio Pulse from

November 14, 2024 | 10:45 pm

RVPH

Reviva Pharmaceuticals Holdings, Inc. (NASDAQ: RVPH) reported its third quarter 2024 financial results and highlighted recent business developments. The company announced that 108 patients have completed a 1-year open-label extension trial for brilaroxazine, with topline data expected in December 2024. Vocal biomarker data from the RECOVER trial supports brilaroxazine's efficacy in treating schizophrenia symptoms.

Portfolio Pulse from

November 14, 2024 | 10:45 pm

SBUX

Starbucks has integrated DoorDash-powered delivery into its app, allowing customers in the US and Canada (excluding Quebec) to order delivery directly through the Starbucks app.

Portfolio Pulse from

November 14, 2024 | 10:30 pm

UTHR

United Therapeutics Corporation has seen a significant stock surge due to strong sales of its PAH treatments, despite facing generic competition. The company's future growth depends on expanding its market for Tyvaso DPI and advancing its pipeline, including IPF treatments and organ transplant technologies.

Portfolio Pulse from

November 14, 2024 | 10:30 pm

EPRX

Eupraxia Pharmaceuticals will present at the American College of Rheumatology Convergence 2024 Annual Meeting, showcasing its DiffuSphere™ technology.

Portfolio Pulse from

November 14, 2024 | 10:15 pm

TMC

TMC the metals company Inc. provided a corporate update and financial results for Q3 2024, focusing on its exploration of battery metals from seafloor polymetallic nodules.

Portfolio Pulse from

November 14, 2024 | 10:15 pm